🇺🇸 FDA
Patent

US 8147840

Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid

granted A61KA61K2039/505A61K2039/53

Quick answer

US patent 8147840 (Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/505, A61K2039/53, A61K2039/555, A61K2039/6056